August 7, 2018

T-cell immunotherapy research expands to more solid tumors

Seattle Children’s has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors.
June 19, 2018

Seattle Children’s Opens Immunotherapy Trial For Children With Relapsed Central Nervous System Tumors

Seattle Children’s has opened a pioneering chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory HER2-positive central nervous system (CNS) tumors where CAR T cells will be delivered directly into the brain.
November 16, 2017

Seattle Children’s Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia that Targets CD22 and CD19 Proteins Simultaneously

By launching a bilateral attack on cancer cells, researchers hope to ultimately increase patients’ long-term remission.
July 27, 2017

Seattle Children’s Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

With 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission in their PLAT-02 trial, researchers at Seattle Children’s are continuing to improve the experimental immunotherapy and reduce the rate of relapse.